Research funder · United States
Neurofibromatosis Therapeutic Acceleration Program
- Grants since 2016
- 90
- Awarded, last 5 years (where amounts are published)
- 32.6M
- Funded works, last 5 years
- 61
- Funded works, all time
- 118
Grants
2016–2017 · award
Investigating the Genetic Epidemic of optic pathway gliomas
Kyle Walsh · The Regents Of The University Of California, San Francisco (contracts & Grants)
2016–2022 · award
Modeling signaling networks of NF1-deficient Schwann cells and plexiform neurofibromas using mass spectrometry-based proteomics
James Walker · Massachusetts General Hospital
2016–2018 · award
A Robust Plexiform Neurofibroma Model for Preclinical Drug Screening
2016–2018 · award
Testing the Pharmacologic role of Molecular Target inhibition on Plexiform Neurofibromas in a Genetically Engineered Mouse Model that closely Phenocopies Human Neurofibromatosis Type 1
D. Wade Clapp
2016–2020 · award
A phase I/II study of the mitogen activated protein kinase (MEK) 1 inhibitor selumetinib (AZD6244; Hyd sulfate) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas
Michael Fisher · Children's Hospital of Philadelphia
2016–2017 · award
NTAP Award - SPORE
Christine Pratilas · Johns Hopkins University
2016–2020 · award
A phase I/II study of the mitogen activated protein kinase (MEK) 1 inhibitor selumetinib (AZD6244; Hyd sulfate) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas
Brian Weiss
2016–2020 · award
Neurofibromatosis Type 1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial
Ashley Cannon · University of Alabama at Birmingham
2015–2022 · award
The Role of MEK-inhibitors for the Prevention and Treatment of Optic Pathway Gliomas in an Nf1 Deficient Mouse Model
Miriam Bornhorst · Children's National
2014–2021 · award
The Development and Validation of PRO Measures to Assess Pain in Individuals with NF1 and pNF
Pamela Wolters · National Cancer Institute